KEGG   DRUG: Favezelimab
Entry
D12469                      Drug                                   
Name
Favezelimab (USAN/INN);
Favezelimab (genetical recombination) (JAN);
Mavezelimab
Formula
C6446H9964N1720O2056S48
Exact mass
145899.4598
Mol weight
145989.59
Sequence
(Heavy chain)
QMQLVQSGPE VKKPGTSVKV SCKASGYTFT DYNVDWVRQA RGQRLEWIGD INPNDGGTIY
AQKFQERVTI TVDKSTSTAY MELSSLRSED TAVYYCARNY RWFGAMDHWG QGTTVTVSSA
STKGPSVFPL APCSRSTSES TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
LYSLSSVVTV PSSSLGTKTY TCNVDHKPSN TKVDKRVESK YGPPCPPCPA PEFLGGPSVF
LFPPKPKDTL MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR
VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL PPSQEEMTKN
QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSRLT VDKSRWQEGN
VFSCSVMHEA LHNHYTQKSL SLSLGK
(Light chain)
DIVMTQTPLS LSVTPGQPAS ISCKASQSLD YEGDSDMNWY LQKPGQPPQL LIYGASNLES
GVPDRFSGSG SGTDFTLKIS RVEAEDVGVY YCQQSTEDPR TFGGGTKVEI KRTVAAPSVF
IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS
STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
(Disulfide bridge: H22-H96, H133-L218, H146-H202, H225-H'225, H228-H'228, H260-H320, H366-H424, H'22-H'96, H'133-L'218, H'146-H'202, H'260-H'320, H'366-H'424, L23-L92, L138-L198, L'23-L'92, L'138-L'198)
  Type
Peptide
Class
Antineoplastic
 DG02938  Immune checkpoint inhibitor
Efficacy
Antineoplastic, Immune checkpoint inhibitor
  Type
Monoclonal antibody
Target
LAG3 (CD223) [HSA:3902] [KO:K06565]
Brite
Drug groups [BR:br08330]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D12469  Favezelimab
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    LAG3 (CD223)
     D12469  Favezelimab (USAN/INN)
Other DBs
CAS: 2231068-83-8
PubChem: 497620882
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system